

## **SUPPLEMENTARY MATERIAL**

eFigure 1. Course of the levels of the biological inflammatory markers LCRP (A), NLR (B) and IL-6 (C) during the visit according to hydroxyzine daily dose. Vertical lines represent standard errors.



eFigure 2. Quantitative bias analysis based on the observed residual differences in age (A) and other patients characteristics (B).



eTable 1. Associations of baseline clinical characteristics with the endpoint of death in the cohort of patients who had been admitted to the hospital for Covid-19 (N=7,345).

					Endpoint of death	
	Full population (N=7,345)	With the end- point event (N=994)	Without the end-point event (N=6,351)	Crude analysis	Multivariable a	nalysis (df=20)
	N (%)	N (%)	N (%)	HR (SE) / p-value	HR (SE) / p-value	Collinearity diagnosis (GVIF <sup>1/(2*df)</sup> )
Age						1.06
18 to 50 years	2709 (36.9%)	42 (4.23%)	2667 (42.0%)	Ref.	Ref.	
51 to 70 years	2530 (34.4%)	240 (24.1%)	2290 (36.1%)	5.31 (0.17) / < 0.001*	2.82 (0.20) / < 0.001	
71 to 80 years	942 (12.8%)	273 (27.5%)	669 (10.5%)	14.86 (0.17) / <0.001*	7.53 (0.20) / < 0.001	
More than 80 years	1164 (15.8%)	439 (44.2%)	725 (11.4%)	16.99 (0.16) / <0.001*	11.35 (0.19) / < 0.001	
Sex						1.06
Women	3619 (49.3%)	359 (36.1%)	3260 (51.3%)	Ref.	Ref.	
Men	3726 (50.7%)	635 (63.9%)	3091 (48.7%)	1.68 (0.07) / < 0.001*	1.32 (0.08) / < 0.001	
Obesity <sup>a</sup>						1.06
Yes	975 (13.3%)	216 (21.7%)	759 (12.0%)	1.51 (0.08) / <0.001*	1.23 (0.09) / 0.021	
No	6370 (86.7%)	778 (78.3%)	5592 (88.0%)	Ref.	Ref.	
Smoking <sup>β</sup>						1.03
Yes	623 (8.48%)	149 (15.0%)	474 (7.46%)	1.51 (0.09) / <0.001*	0.93 (0.10) / 0.452	
No	6722 (91.5%)	845 (85.0%)	5877 (92.5%)	Ref.	Ref.	
Number of medical						
conditions <sup>\gamma</sup>						1.12
0	4750 (64.7%)	319 (32.1%)	4431 (69.8%)	Ref.	Ref.	
1	534 (7.27%)	63 (6.34%)	471 (7.42%)	2.29 (0.14) / <0.001*	1.78 (0.16) / <0.001	
2 or more	2061 (28.1%)	612 (61.6%)	1449 (22.8%)	4.71 (0.07) / <0.001*	3.49 (0.09) / <0.001	

Medication according to						
compassionate use or as part						1.11
of a clinical trial $^{\Theta}$						
Yes	1288 (17.5%)	226 (22.7%)	1062 (16.7%)	1.13 (0.08) / 0.105	0.74 (0.09) / 0.001	
No	6057 (82.5%)	768 (77.3%)	5289 (83.3%)	Ref.	Ref.	
Anxiety or insomnia $^{\epsilon}$						1.04
Yes	299 (4.07%)	101 (10.2%)	198 (3.12%)	2.38 (0.11) / <0.001*	1.24 (0.12) / 0.062	
No	7046 (95.9%)	893 (89.8%)	6153 (96.9%)	Ref.	Ref.	
Any other antihistamine						1.01
medication						1.01
Yes	100 (1.4%)	16 (1.6%)	84 (1.3%)	0.94 (0.25) / 0.799	0.67 (0.29) / 0.160	
No	7245 (98.6%)	978 (98.4%)	6267 (98.7%)	Ref.	Ref.	
SSRI or SNRI						1.08
Yes	318 (4.3%)	81 (8.15%)	237 (3.73%)	1.5 (0.12) / <0.001*	0.66 (0.12) / 0.001	
No	7027 (95.7%)	913 (91.9%)	6114 (96.3%)	Ref.	Ref.	
Any other antidepressant						1.05
Yes	142 (1.93%)	47 (4.73%)	95 (1.50%)	2.03 (0.15) < 0.001*	0.85 (0.17) / 0.340	
No	7203 (98.1%)	947 (95.3%)	6256 (98.5%)	Ref.	Ref.	
Any mood stabilizer						1.05
medication $^{\Omega}$						1.05
Yes	287 (3.91%)	69 (6.94%)	218 (3.43%)	1.42 (0.12) / 0.005*	0.93 (0.14) / 0.587	
No	7058 (96.1%)	925 (93.1%)	6133 (96.6%)	Ref.	Ref.	
Any benzodiazepine or Z-						1.14
drug						1.14
Yes	752 (10.2%)	268 (27.0%)	484 (7.62%)	2.53 (0.07) / <0.001*	1.56 (0.09) / < 0.001	
No	6593 (89.8%)	726 (73.0%)	5867 (92.4%)	Ref.	Ref.	
Any antipsychotic						1.07

Yes	264 (3.59%)	60 (6.04%)	204 (3.21%)	1.26 (0.13) / 0.086	0.80 (0.14) / 0.120	
No	7081 (96.4%)	934 (94.0%)	6147 (96.8%)	Ref.	Ref.	
Clinical severity of Covid-19						1 15
at admission <sup>µ</sup>						1.15
Yes	1564 (21.3%)	421 (42.4%)	1143 (18.0%)	1.81 (0.08) / <0.001*	1.69 (0.09) / <0.001	
No	1858 (25.3%)	265 (26.7%)	1593 (25.1%)	Ref.	Ref.	
Missing	3923 (53.4%)	308 (31.0%)	3615 (56.9%)	0.59 (0.08) / <0.001*	1.66 (0.11) / < 0.001	
Biological severity of Covid-						1 15
19 at admission <sup>κ</sup>						1.15
Yes	2439 (33.2%)	592 (59.6%)	1847 (29.1%)	1.94 (0.08) / <0.001*	1.51 (0.09) / <0.001	
No	1861 (25.3%)	257 (25.9%)	1604 (25.3%)	Ref.	Ref.	
Missing	3045 (41.5%)	145 (14.6%)	2900 (45.7%)	0.39 (0.1) / <0.001*	0.75 (0.12) / 0.022	

<sup>&</sup>lt;sup>α</sup> Defined as having a body-mass index higher than 30 kg/m<sup>2</sup> or an International Statistical Classification of Diseases and Related Health Problems (ICD-10) diagnosis code for obesity (E66.0, E66.1, E66.2, E66.8, E66.9).

Abbreviations: HR, hazard ratio; SE, standard error; GVIF, generalized variance inflation factor.

<sup>&</sup>lt;sup>β</sup> Smoking status was self-reported.

<sup>&</sup>lt;sup>γ</sup> Assessed using ICD-10 diagnosis codes for diabetes mellitus (E11), diseases of the circulatory system (I00-I99), diseases of the respiratory system (J00-J99), neoplasms (C00-D49), diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D5-D8), delirium (F05, R41) and dementia (G30, G31, F01-F03).

<sup>&</sup>lt;sup>6</sup> Any medication prescribed as part of a clinical trial or according to compassionate use (e.g., hydroxychloroquine, azithromycin, remdesivir, tocilizumab, sarilumab or dexamethasone).

<sup>&</sup>lt;sup>€</sup> Assessed using ICD-10 diagnosis codes for anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders (F40-F48) and insomnia (G47).

<sup>&</sup>lt;sup>Ω</sup> Included lithium or antiepileptic medications with mood stabilizing properties.

 $<sup>^{\</sup>mu}$  Defined as having at least one of the following criteria: respiratory rate > 24 breaths/min or < 12 breaths/min, resting peripheral capillary oxygen saturation in ambient air < 90%, temperature > 40°C, or systolic blood pressure < 100 mm Hg.

<sup>&</sup>lt;sup>K</sup> Defined as having at least one of the following criteria: high neutrophil-to-lymphocyte ratio, low lymphocyte-to-C-reactive protein (both variables were dichotomized at the median of the values observed in the full sample), and plasma lactate levels higher than 2 mmol/L.

<sup>\*</sup> p-value is significant (p<0.05).

eTable 2. Association between hydroxyzine use within the 3 months prior to hospital admission and not during the visit for COVID-19 and the endpoint of death in the full sample and in the matched analytic sample.

	Number of events / Number of patients	Crude Cox regression analysis	Multivariable Cox regression analysis	Analysis weighted by inverse-probability-weighting weights	Number of events / Number of patients	Univariate Cox regression in matched analytic samples
	N (%)	HR (95% CI; p-value)	HR (95% CI; p-value) (df=23)	HR (95% CI; p-value)	N (%)	HR (95% CI; p-value)
Hydroxyzine use during the visit for COVID-19	12 / 125 (9.6%)	Ref.	Ref.	Ref.	12 / 125 (9.6%)	Ref.
Hydroxyzine only within the last 3 months prior to the visit	19 / 51 (37.3%)	3.25 (1.58 - 6.71; 0.001*)	3.43 (1.65 – 7.12; 0.001*)	3.28 (1.54 – 6.98; 0.002*)	19 / 51 (37.3%)	3.02 (1.46 – 6.24; 0.003*)
Hydroxyzine use within the last 3 months and during the visit	3 / 13 (23.1%)	2.07 (0.59 – 7.36; 0.258)	2.88 (0.80 – 10.30; 0.104)	2.05 (0.57 – 7.46; 0.274)	3 / 13 (23.1%)	1.85 (0.52 – 6.59; 0.340)
No hydroxyzine	960 / 7,156 (13.4%)	1.84 (1.04 – 3.25; 0.036*)	2.60 (1.47 – 4.63; 0.001*)	3.02 (1.68 – 5.42; <0.001*)	42 / 189 (22.2%)	2.94 (1.55 – 5.59; 0.001*)

<sup>\*</sup> p-value is significant (p<0.05).

eTable 3. Comparing the associations of hydroxyzine use and zopiclone use with the endpoint of death in the full sample and in the matched analytic sample.

	Number of events / Number of patients	Crude Cox regression analysis	Multivariable Cox regression analysis	Analysis weighted by inverse- probability- weighting weights	Number of events / Number of patients	Univariate Cox regression in the matched analytic sample (1:1)
	N (%)	HR (95% CI; p-value)	HR (95% CI; p-value) (df=24)	HR (95% CI; p-value)	N (%)	HR (95% CI; p-value)
Zopiclone	46 / 151 (30.5%)	Ref.	Ref.	Ref.	4 / 12 (33.3%)	Ref.
Hydroxyzine	14 / 129 (10.9%)	0.38 (0.21 - 0.70; 0.002*)	0.39 (0.21 – 0.73; 0.003*)	0.32 (0.15 – 0.70; 0.004*)	14 / 129 (10.9%)	0.27 (0.09 – 0.83; 0.022*)
Hydroxyzine and Zopiclone	1 / 9 (1.1%)	0.27 (0.04 - 2.00; 0.201)	0.29 (0.04 – 2.43; 0.255)	0.06 (0.01 – 0.49; 0.009*)	1 / 9 (1.1%)	0.19 (0.02 – 1.68; 0.135)
No hydroxyzine or Zopiclone	933 / 7056 (13.2%)	0.61 (0.0.45 - 0.82; 0.001*)	0.85 (0.62 – 1.16; 0.305)	0.74 (0.51 – 1.08; 0.116)	49 / 264 (18.6%)	0.61 (0.22 – 1.70; 0.349)

<sup>\*</sup> p-value is significant (p<0.05).

eTable 4. Associations between hydroxyzine daily dose and the endpoint of death among patients using hydroxyzine during the visit (N=138).

	Number of events / Number of patients	Crude Cox regression analysis	Cox regression adjusted for age and sex	Multivariable Cox regression analysis
	N (%)	HR (95% CI; p-value)	HR (95% CI; p-value) (df=6)	HR (95% CI; p-value) (df=22)
Daily dose				
Lower doses	8 / 53 (15.1%)	Ref.	Ref.	Ref.
Higher doses	2 / 53 (3.8%)	0.11 (0.02 – 0.48; 0.004*)	0.12 (0.03 – 0.57; 0.007*)	0.10 (0.02 – 0.45; 0.003*)

\* p-value is significant (p<0.05). Because daily dose could not be ascertained with certainty in 32 (23.2%) patients, these patients have been excluded from this analysis. The variable 'daily dose' has been dichotomized by the median.

eTable 5. Association between levels of the biological inflammatory markers NLR, LCRP, IL-6 and lactates and the endpoint of death in the subsamples of patients with COVID-19 who had at least two measures of each marker during the visit.

	Fir	st measure	Las	st measure
	Number of events / Number of patients	Crude Cox regression analysis <sup>α</sup>	Number of events / Number of patients	Crude Cox regression analysis <sup>a</sup>
	Events / N (%)	HR (95% CI; p-value)	Events / N (%)	HR (95% CI; p-value)
Biological inflammatory markers	426 / 1 970 (22 70/)	0.92 (0.76 0.00, <0.001*)	422 / 1 977 (22 50/)	0.47 (0.42 - 0.60, <0.001*)
LCRP	426 / 1,879 (22.7%)	0.83 (0.76 - 0.90; <0.001*)	423 / 1,876 (22.5%)	0.47 (0.43 - 0.60; <0.001*)
NLR	492 / 2,158 (22.8%)	1.26 (1.11 - 1.43; <0.001*)	493 / 2,159 (22.8%)	2.71 (2.47 - 2.96; <0.001*)
IL-6	53 / 315 (16.8%)	1.29 (1.06 - 1.57; 0.010*)	53 / 3,15 (16.8%)	1.53 (1.33 - 1.76; <0.001*)
Lactates	319 / 1,159 (27.5%)	1.27 (0.79 – 2.03; 0.326)	823 / 1,163 (27.8%)	2.75 (2.43 – 3.13; <0.001*)

 $<sup>^{\</sup>alpha}$  Values were log-transformed to address non-normal distribution of the biological variables.

eTable 6. Course of the levels of the biological inflammatory markers NLR, LCRP, IL-6 and lactates during the visit according to hydroxyzine use.

	Full population	Exposed to hydroxyzine	Not exposed to hydroxyzine	Two-way ANOVA: Interaction term
	N / Mean (SD)	N / Mean (SD)	N / Mean (SD)	F (p) α
Biological inflammatory				
markers				
LCRP				16.33 (<0.001*)
First measurement	1,879 / 695.1 (2,732.0)	63 / 308.4 (666.3)	1,816 / 708.5 (2,775.3)	` '
Last measurement	1,879 / 1,396.2 (3,831.7)	63 / 1,640.5 (2,673.9)	1,816 / 1,387.7 (3,865.9)	
NLR				14.80 (<0.001*)
First measurement	2,161 / 7.1 (6.8)	72 / 8.3 (6.8)	2,089 / 7.1 (6.8)	,
Last measurement	2,161 / 6.8 (9.1)	72 / 4.9 (5.8)	2,089 / 6.8 (9.2)	
IL-6				5.87 (0.016*)
First measurement	315 / 182.4 (405.7)	10/216.2 (230.1)	305 / 181.2 (410.4)	,
Last measurement	315 / 238.1 (800.2)	10 / 51.9 (68.6)	305 / 244.2 (812.4)	
Lactates				0.94 (0.333)
First measurement	1,142 / 1.5 (0.8)	43 / 1.4 (0.7)	1,099 / 1.5 (0.8)	,
Last measurement	1,142 / 1.5 (1.3)	43 / 1.2 (0.5)	1,099 / 1.6 (1.3)	

<sup>&</sup>lt;sup>a</sup> Values were log-transformed to address non-normal distribution of the biological variables.

<sup>\*</sup> p-value is significant (p<0.05).

eTable 7. Course of the levels of the biological inflammatory markers NLR, LCRP, and IL-6 during the visit according to hydroxyzine dose.

	Full population	Low dosage	High dosage	Two-way ANOVA: Interaction term
	N / Mean (SD)	N / Mean (SD)	N / Mean (SD)	$F(p)^{\alpha}$
Biological inflammatory markers				
LCRP				4.57 (0.037*)
First measurement	55 / 329.2 (708.6)	25 / 273.5 (399.4)	30 / 375.6 (893.4)	
Last measurement	55 / 1,423.8 (2,016.8)	25 / 957.2 (1,728.3)	30 / 1,812.7 (2,181.2)	
NLR				5.62 (0.021*)
First measurement	60 / 8.6 (7.2)	26 / 6.3 (4.1)	34 / 10.4 (8.4)	
Last measurement	60 / 4.6 (5.0)	26 / 5.7 (7.0)	34 / 3.8 (2.6)	
IL-6				0.62 (0.454)
First measurement	10 / 216.2 (230.1)	5 / 95.5 (148.4)	337.0 (246.3)	
Last measurement	10 / 51.9 (68.6)	5 / 35.5 (52.3)	68.4 (84.7)	

 $<sup>^{\</sup>alpha}$  Values were log-transformed to address non-normal distribution of the biological variables. \* p-value is significant (p<0.05).